We are pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner.

We’re very pleased to share with you that MedaSystems has closed a seed funding round, in order to continue to grow our market and further build out the platform.